Trial Site News
Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
  • Register
  • Log In
  • News
  • Video
  • Podcast
  • More
Trial Site News
  • News For You
  • Op-Eds
  • Video
  • Podcasts
  • Investor Watch
  • Write for us
  • News for You
  • Op-Eds
  • Video
  • Podcasts
  • Covid-19
  • Investor Watch

Topic: UC Davis

UC Davis Health Ramps Up Project Lightspeed: Serves as Trial Site for Phase 2/3 BNT162 COVID-19 Vaccine Study

UC Davis Health was one of about 120 trial sites selected worldwide to participate in the Phase 2/3 stage testing […]

UC Davis Health Ramps Up Project Lightspeed Serves as Trial Site for Phase 23 BNT162 COVID-19 Vaccine Study
7 months ago
Share

UC Davis Selected to Participate in the REGN-COV2 Clinical Trial Investigating Monoclonal Antibody Targeting COVID-19

UC Davis Health investigators, thanks to a recent federal grant, are preparing to test a promising new antibody cocktail, known […]

UC Davis Selected to Participate in the REGN-COV2 Clinical Trial Investigating Monoclonal Antibody Targeting COVID-19
8 months ago
Share

UC Davis Researchers benefit from Recent COVID-19 Grants

UC Davis researchers have a role in eight of the 25 COVID-19-related projects that recently received seed grants from CITRIS […]

UC Davis Researchers benefit from Recent COVID-19 Grants
9 months ago
Share

Will Clinical Research Grow in California’s Capital?

Just as the death toll from COVID-19 rose over 90,000 in the United States, Operation Warp Speed was announced by […]

Will Clinical Research Grow in California’s Capital
10 months ago
Share

UC Davis Spinoff with Novel Antigen Specific Therapy Targeting Autoimmune Diseases Seeks Investors

A University of California, Davis (UCD) spinoff is developing a new therapeutic approach to treat autoimmune diseases. UCD researchers and […]

UC Davis Spinoff with Novel Antigen Specific Therapy Targeting Autoimmune Diseases Seeks Investors
12 months ago
Share

UC Davis Invests $4M to Launch New Research Centers: IMPACT

UC Davis will infuse $4 million over the next three years to launch four new research centers that align the […]

UC Davis Invests $4M to Launch New Research Centers: IMPACT
1 year ago
Share

UC Davis Joins U.S. POINTER Study: Does Healthy Lifestyle Reduce Alzheimer’s Risk?

The Alzheimer’s Association gave $6 million to the University of California, Davis, to fund its participation in the U.S. POINTER […]

healthy eating concept
2 years ago
Share

UC Davis IP Spins Out into Venture & Secures $5 Million

UC Davis, CA-based venture targeting chronic pain receives a $5 million investment from Open Philanthropy.  The goal is to move […]

Chronic Pain
2 years ago
Share

Record Number of UC Davis Spinoffs During Fiscal 2018 Year

Lisa Howard writing for University of California Davis reports a record number of new ventures during the fiscal 2018 year. […]

2 years ago
Share

UC Davis Study Pages Helps Volunteer Patients Find Clinical Trials

Study Pages was developed by UC Davis.  UC Davis Health’s mission is to discovery and share knowledge to advance health. […]

3 years ago
Share

Posts navigation

Older posts

Latest Podcasts

Alan Cannell talks COVID-19: Nobody Likes Cheap Solutions | Podcast S2 E41

Dr. Pierre Kory Talks Covid-19, Ivermectin and the FLCCC | Podcast E43

An Interview With Patricia Carter: Patient Engagement and Retention in Clinical Trials

Dr. Negin Hajizadeh: Researchers Finding A Very Effective Treatment For Covid-19 In New Study

Dr. Jean-Jacques Rajter and Dr. Juliana Cepelowicz Rajter Discuss Ivermectin In Broward County | Podcast S2 E 27

159 W Broadway, Suite 200
Salt Lake City, UT 84101

[email protected]

Connect With Us

TRIALSITE NEWS IS THE ONLY DIGITAL MEDIA DEDICATED 100% TO TRANSPARENT AND OPEN COVERAGE OF CLINICAL RESEARCH TRIAL SITES AROUND THE GLOBE. BASED IN THE SILICON SLOPES IN DOWNTOWN SALT LAKE CITY, UTAH, WE ARE FOUNDED BY A TEAM OF EXPERTS IN THE CLINICAL TRIALS INDUSTRY AND DEDICATED TO TRANSPARENCY, QUALITY AND CLINICAL TRIAL INNOVATION.

© 2021 TRIALSITE NEWS. ALL RIGHTS RESERVED.